<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04167228</url>
  </required_header>
  <id_info>
    <org_study_id>FCO-CAV-2018-01</org_study_id>
    <nct_id>NCT04167228</nct_id>
  </id_info>
  <brief_title>Impact of Ceftazidime / Avibactam Treatment vs Better Available Therapy on Mortality of Patients With Infections Caused by Carbapenem-resistant Enterobacteria</brief_title>
  <acronym>CAVICOR</acronym>
  <official_title>Impact of Ceftazidime / Avibactam Treatment vs Better Available Therapy on Mortality of Patients With Infections Caused by Carbapenem-resistant Enterobacteria</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Maimónides Biomedical Research Institute of Córdoba</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Maimónides Biomedical Research Institute of Córdoba</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Patients with infections caused by carbapenem-resistant enterobacteria treated with CAZ-AVI
      versus patients treated with BAT are compared. The BAT group includes fosfomycin,
      tigecycline, gentamicin, meropenem and colistin.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Carbapenem-resistant enterobacteria (CRE) are a public health problem. The morbidity and
      mortality of patients with invasive infections due to CRE are high. The best treatment is
      unknown, however, combination therapy with at least 2 active drugs is often recommended for
      high-risk patients, and monotherapy is probably not inferior to this in low-risk patients.

      Ceftazidime-avibactam is active against many CRE, and in some countries it has been
      prescribed under compassionate use programs for these infections; It has recently been
      approved by the FDA and the EMA for specific indications. Recent data suggest that
      ceftazidime-avibactam may be superior for the treatment of infections caused by sensitive
      CRE, rather than traditional regimens that often include colistin, usually combined with
      other drugs. However, these studies include a low number of patients and are subject to
      important biases.

      Additionally, the development of resistance to this drug during / after treatment has been
      described and is worrying.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 11, 2019</start_date>
  <completion_date type="Anticipated">June 2020</completion_date>
  <primary_completion_date type="Anticipated">June 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>30-day mortality rate</measure>
    <time_frame>At day 30 after the start of the treatment</time_frame>
    <description>To describe the 30-day mortality rate in the caz-avi group and in the group with the best available therapy of patients with infections caused by carbapenem-resistant enterobacteria.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Clinical response on day 21</measure>
    <time_frame>At day 21 after the start of the treatment</time_frame>
    <description>To describe the clinical response on day 21 of the caz-avi group and in the group with the best available therapy of patients with infections caused by carbapenem-resistant enterobacteria.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Microbiological response</measure>
    <time_frame>At day 30 after the start of the treatment</time_frame>
    <description>Microbiological response in the Test-of-cure, categorized as eradication, microbiological failure or uncertain.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>30-day mortality rate in the group of patients with caz-avi in monotherapy and in the group with combined therapy with caz-avi</measure>
    <time_frame>At day 30 after the start of the treatment</time_frame>
    <description>Describe the 30-day mortality rate in the group of patients with caz-avi in monotherapy and in the group with combined therapy with caz-avi, who present with infections caused by carbapenem-resistant enterobacteria.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Risk factors associated with the development of resistance to ceftazidime-avibactam during treatmen</measure>
    <time_frame>At day 30 after the start of the treatment</time_frame>
    <description>Describe the rates and risk factors associated with the development of resistance to ceftazidime-avibactam (MIC&gt; 8 microg / mL) during treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of hospital stay after infection</measure>
    <time_frame>At day 30 after the start of the treatment</time_frame>
    <description>Number of days elapsed from the end of antibiotic treatment until discharge and duration of ICU stay if appropriate.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of antibiotic treatment during the episode</measure>
    <time_frame>At day 30 after the start of the treatment</time_frame>
    <description>Number of days of antibiotic treatment during the episode</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Recurrence</measure>
    <time_frame>At day 30 after the start of the treatment</time_frame>
    <description>Reappearance of the infection according to the same criteria and by the same microorganism</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety evaluation of the treatment</measure>
    <time_frame>At day 30 after the start of the treatment</time_frame>
    <description>Number of adverse reactions related to therapy</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">348</enrollment>
  <condition>Carbapenem-Resistant Enterobacteriaceae Infection</condition>
  <arm_group>
    <arm_group_label>CRE infected patients treated with ceftazidime-avibactam</arm_group_label>
    <description>Patients with infections caused by carbapenem resistant enterobacteria treated with ceftazidime-avibactam</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CRE infected patients treated with best available treatment</arm_group_label>
    <description>Patients with infections caused by carbapenem resistant enterobacteria treated with the best available treatment</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ceftazidime-Avibactam</intervention_name>
    <description>Patients with complicated urinary tract infections, nosocomial pneumonia (including pneumonia associated with ventilation), complicated intra-abdominal infections or bacteremia (if the focus of infection is any of the above, the patient should be included in both groups) due to CRE, treated &gt; 2 days with ceftazidime-avibactam.</description>
    <arm_group_label>CRE infected patients treated with ceftazidime-avibactam</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Best Available Therapy</intervention_name>
    <description>Patients with complicated urinary tract infections, nosocomial pneumonia (including pneumonia associated with ventilation), complicated intra-abdominal infections or bacteremia (if the focus of infection is any of the above, the patient should be included in both groups) due to CRE, treated &gt; 2 days with the best available treatment other than ceftazidime-avibactam.</description>
    <arm_group_label>CRE infected patients treated with best available treatment</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with infections caused by carbapenem resistant enterobacteria
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with complicated urinary tract infections, nosocomial pneumonia (including
             pneumonia associated with ventilation), complicated intra-abdominal infections or
             bacteremia (if the focus of infection is any of the above, the patient should be
             included in both groups) due to CRE, treated &gt; 2 days with ceftazidime-avibactam.
             Patients with bacteremia can be included in one of the other cohorts if the focus of
             the infection is the urinary tract, respiratory tract or an intra-abdominal infection
             and they meet the appropriate criteria (see below). The retrospective design of this
             study has been carried out to avoid the induction of the prescription of
             ceftazidime-avibactam in each center. For this, patients will be included at the end
             of the period of evaluation of the primary objective (crude mortality at day 30). If
             more than one patient can be used as a control, the one with the closest admission
             date will be chosen.

        Control: local historical cohort - Patients treated with ceftazidime-avibactam will be
        compared with patients treated with BAT. Because after approval of the use of
        ceftazidime-avibactam, BAT could be used less frequently to treat this type of infection,
        patients treated with BAT from January 1, 2014 will be included. These patients will be
        matched by hospital, type of hospital. infection (urinary tract vs others) and INCREMENT
        score.

        Exclusion Criteria:

          -  The infection is considered polymicrobial according to the standard microbiological
             interpretation of the crop results (except for complicated intra-abdominal infections,
             in which case, polymicrobial infections are allowed).

          -  Patients with infections caused by CRE without susceptibility to
             ceftazidime-avibactam.

          -  The patient is participating in a clinical trial that involves active treatment for
             infections.

          -  Patients with cardiopulmonary no resuscitation order or with a life expectancy &lt; 30
             days.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Juan José Castón Osorio, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Universitario Reina Sofía</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Antonio Miguel Luque Pineda</last_name>
    <phone>0034 957 011 040</phone>
    <email>antonio.luque@imibic.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>Hospital Universitario de Bellvitge</name>
      <address>
        <city>Hospitalet de Llobregat</city>
        <state>Barcelona</state>
        <zip>08907</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jordi Carratalà Fernández, MD</last_name>
    </contact>
    <investigator>
      <last_name>Jordi Carratalà Fernández, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario de Gran Canaria &quot;Dr. Negrín&quot;</name>
      <address>
        <city>Las Palmas De Gran Canaria</city>
        <state>Canary Islands</state>
        <zip>35019</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Óscar Sanz Peláez, MD</last_name>
    </contact>
    <investigator>
      <last_name>Óscar Sanz Peláez, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Marqués de Valdecilla</name>
      <address>
        <city>Santander</city>
        <state>Cantabria</state>
        <zip>39008</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>María del Carmen Fariñas Álvarez, MD</last_name>
    </contact>
    <investigator>
      <last_name>María del Carmen Fariñas Álvarez, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Complejo Hospitalario Universitario A Coruña</name>
      <address>
        <city>A Coruña</city>
        <state>Coruña</state>
        <zip>15006</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Enrique Miguez Rey, MD</last_name>
    </contact>
    <investigator>
      <last_name>Enrique Miguez Rey, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Álvaro Cunqueiro</name>
      <address>
        <city>Vigo</city>
        <state>Pontevedra</state>
        <zip>36211</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>María Teresa Pérez Rodríguez, MD</last_name>
    </contact>
    <investigator>
      <last_name>María Teresa Pérez Rodríguez, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Vall d'Hebrón</name>
      <address>
        <city>Barcelona</city>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Benito Almirante Gragera, MD</last_name>
    </contact>
    <investigator>
      <last_name>Benito Almirante Gragera, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Clínico de Barcelona</name>
      <address>
        <city>Barcelona</city>
        <zip>08036</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alex Soriano Viladomiu, MD</last_name>
    </contact>
    <investigator>
      <last_name>Alex Soriano Viladomiu, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital San Pedro de Alcántara</name>
      <address>
        <city>Cáceres</city>
        <zip>10003</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>María del Carmen Pazos Pacheco, MD</last_name>
    </contact>
    <investigator>
      <last_name>María del Carmen Pazos Pacheco, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Reina Sofía</name>
      <address>
        <city>Córdoba</city>
        <zip>14004</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antonio Miguel Luque Pineda</last_name>
      <phone>0034 957 011 040</phone>
      <email>antonio.luque@imibic.org</email>
    </contact>
    <investigator>
      <last_name>Juan José Castón Osorio, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario de La Princesa</name>
      <address>
        <city>Madrid</city>
        <zip>28006</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Fernando Ramasco Rueda, MD</last_name>
    </contact>
    <investigator>
      <last_name>Fernando Ramasco Rueda, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital General Universitario Gregorio Marañón</name>
      <address>
        <city>Madrid</city>
        <zip>28007</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Patricia Muñoz García, MD</last_name>
    </contact>
    <investigator>
      <last_name>Patricia Muñoz García, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Ramón y Cajal</name>
      <address>
        <city>Madrid</city>
        <zip>28034</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Vicente Pintado García, MD</last_name>
    </contact>
    <investigator>
      <last_name>Vicente Pintado García, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario 12 de Octubre</name>
      <address>
        <city>Madrid</city>
        <zip>28041</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>José María Aguado García, MD</last_name>
    </contact>
    <investigator>
      <last_name>José María Aguado García, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Regional Universitario de Málaga</name>
      <address>
        <city>Málaga</city>
        <zip>29010</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>José María Reguera Iglesias, MD</last_name>
    </contact>
    <investigator>
      <last_name>José María Reguera Iglesias, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Clínico Universitario de Valencia</name>
      <address>
        <city>Valencia</city>
        <zip>46010</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gerardo Aguilar Aguilar, MD</last_name>
    </contact>
    <investigator>
      <last_name>Gerardo Aguilar Aguilar, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital General Universitario de Valencia</name>
      <address>
        <city>Valencia</city>
        <zip>46014</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Vicente Abril López de Medrano, MD</last_name>
    </contact>
    <investigator>
      <last_name>Vicente Abril López de Medrano, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario y Politécnico La Fe</name>
      <address>
        <city>Valencia</city>
        <zip>46026</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Paula Ramírez Galleymore, MD</last_name>
    </contact>
    <investigator>
      <last_name>Paula Ramírez Galleymore, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>November 14, 2019</study_first_submitted>
  <study_first_submitted_qc>November 15, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">November 18, 2019</study_first_posted>
  <last_update_submitted>February 18, 2020</last_update_submitted>
  <last_update_submitted_qc>February 18, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 19, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>ceftazidime / avibactam</keyword>
  <keyword>carbapenem resistant enterobacteria</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infection</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>Enterobacteriaceae Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ceftazidime</mesh_term>
    <mesh_term>Avibactam</mesh_term>
    <mesh_term>Avibactam, ceftazidime drug combination</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>The information collected will be of public access by request.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_time_frame>After the trial results are public.</ipd_time_frame>
    <ipd_access_criteria>By request to uicec@imibic.org</ipd_access_criteria>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

